|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: CTAG2 |
Gene summary for CTAG2 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | CTAG2 | Gene ID | 30848 |
| Gene name | cancer/testis antigen 2 | |
| Gene Alias | CAMEL | |
| Cytomap | Xq28 | |
| Gene Type | protein-coding | GO ID | GO:0006139 | UniProtAcc | O75638 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 30848 | CTAG2 | S014 | Human | Liver | HCC | 9.74e-67 | 2.05e+00 | 0.2254 |
| 30848 | CTAG2 | S015 | Human | Liver | HCC | 1.21e-31 | 1.32e+00 | 0.2375 |
| 30848 | CTAG2 | S016 | Human | Liver | HCC | 9.74e-48 | 1.65e+00 | 0.2243 |
| 30848 | CTAG2 | ATC09 | Human | Thyroid | ATC | 1.26e-19 | 6.41e-01 | 0.2871 |
| 30848 | CTAG2 | ATC1 | Human | Thyroid | ATC | 3.66e-21 | 7.73e-01 | 0.2878 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| CTAG2 | SNV | Missense_Mutation | novel | c.582N>G | p.Asp194Glu | p.D194E | O75638 | protein_coding | deleterious_low_confidence(0) | benign(0.003) | TCGA-A8-A07J-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | 5-fluorouracil | CR |
| CTAG2 | insertion | In_Frame_Ins | novel | c.583_584insTCAGCATTA | p.Gly195delinsValSerIleArg | p.G195delinsVSIR | O75638 | protein_coding | TCGA-A8-A07J-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | 5-fluorouracil | CR | ||
| CTAG2 | SNV | Missense_Mutation | rs782496546 | c.317N>A | p.Arg106His | p.R106H | O75638 | protein_coding | tolerated_low_confidence(0.26) | probably_damaging(0.984) | TCGA-C5-A3HE-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | PD |
| CTAG2 | SNV | Missense_Mutation | c.467G>T | p.Gly156Val | p.G156V | O75638 | protein_coding | deleterious_low_confidence(0) | benign(0.255) | TCGA-AY-A54L-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| CTAG2 | SNV | Missense_Mutation | rs373719423 | c.212C>T | p.Ala71Val | p.A71V | O75638 | protein_coding | deleterious_low_confidence(0.03) | benign(0.293) | TCGA-G4-6588-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| CTAG2 | SNV | Missense_Mutation | rs200770651 | c.199N>A | p.Gly67Ser | p.G67S | O75638 | protein_coding | tolerated_low_confidence(0.25) | benign(0.003) | TCGA-G4-6626-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
| CTAG2 | SNV | Missense_Mutation | rs782686361 | c.412C>T | p.Arg138Trp | p.R138W | O75638 | protein_coding | deleterious_low_confidence(0.03) | possibly_damaging(0.89) | TCGA-EI-6917-01 | Colorectum | rectum adenocarcinoma | Male | <65 | III/IV | Chemotherapy | 5fluorouracil+oxaciplatina+l-folinian | SD |
| CTAG2 | SNV | Missense_Mutation | novel | c.560C>T | p.Pro187Leu | p.P187L | O75638 | protein_coding | deleterious_low_confidence(0) | benign(0.022) | TCGA-A5-A0G1-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| CTAG2 | SNV | Missense_Mutation | rs782686361 | c.412N>T | p.Arg138Trp | p.R138W | O75638 | protein_coding | deleterious_low_confidence(0.03) | possibly_damaging(0.89) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| CTAG2 | SNV | Missense_Mutation | c.467G>A | p.Gly156Glu | p.G156E | O75638 | protein_coding | deleterious_low_confidence(0) | benign(0.255) | TCGA-A5-A0R7-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 30848 | CTAG2 | NA | AUTOLOGOUS ANTI-NY-ESO-1/LAGE-1 TCR-TRANSDUCED C259 T LYMPHOCYTES GSK3377794 | 26193344 |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |